Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and secondary prevention of venous thromboembolism (VTE). The optimal duration of anticoagulation has been an active area of clinical investigation for patients undergoing orthopedic surgeries and those diagnosed with a first episode of unprovoked VTE. Practice guidelines, VTE incidence, clinical predictors/mediators, and clinical trial evidence is reviewed to help pharmacists and other health care providers make an informed, patient-specific decision on the optimal duration of anticoagulation therapy. Extended anticoagulation up to 5 weeks following orthopedic surgery for primary VTE prevention and indefinitely following a first episode of unprovoked VTE for secondary VTE prevention should be considered only if the risk of bleeding is not high and the cost and burden of anticoagulation is acceptable to the patient. The optimal duration of anticoagulation therapy for primary or secondary prevention of VTE should include the health care provider and patient making a decision based on evaluation of individual benefits, risks, and preferences.
WhiteRH. The epidemiology of venous thromboembolism. Circulation2003;107(23 suppl 1):I4–I8.
2.
HorlanderKTManninoDMLeeperKV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med. 2003;163(14):1711–1777.
3.
KearonCKahnSRAgnelliG. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(6 suppl):454–545.
SnowVQaseemABarryP. Management of venous thromboembolism: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007;146(3):204–210.
6.
GeertsWHBergqvistDPineoGF. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guideline (8th edition). Chest. 2008;133(6 suppl):381S–453S.
7.
AndersonFAWhiteK. Prolonged prophylaxis in orthopedic surger; insights from the United States. Semin Thromb Haemost. 2002;28(suppl 3):43–46.
8.
HowellB. Joint surgery: paving the way a smooth recovery. RN. 2007;70(1):32–38.
9.
JohansonNALachiewiczPFLiebermanJR. Prevention of symptomatic pulmonary embolism in patient undergoing total hip or knee arthroplasty. J Am Acad Orthop Surg. 2009;17(3):183–196.
10.
EikelboomJWKarthikeyanGFagelN. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thrombembolism prevention in hip and knee arthroplasty differ. Chest. 2009;135(2):513–520.
11.
ArnesonHDahlOEAspelinT. Sustained prothrombrotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost. 2003;1(5):971–975.
12.
DahlOEAspelinTArnesenH. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res. 1995;80(4):299–306.
13.
BjornaraBTGudmundsenTEDahlOE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg. 2006;88(3):386–391.
14.
WhiteRHRomanoPSZhouH. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158(14):1525–1531.
15.
KolbGBodamerIGalsterH. Reduction of venous thromboembolism following prophylaxis with the low molecular weight heparin certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thromb Haemost. 2003;90(6):1100–1105.
16.
CompPCSpiroTEFriedmanRJ. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg. 2001;83-A(3):336–345.
17.
ErikssonBILassenMR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Arch Intern Med. 2003;163(11):1337–1342.
18.
HullRDPineoGFSteinPD. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001;135(10):858–869.
19.
ArcelusJIMonrealMCapriniJA. Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE registry. Thromb Haemost. 2008;99(3):546–551.
20.
WhiteRHGettnerSNewmanJM. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000;343(24):1758–1764.
21.
BuehlerKOD’LimaDDPetersilgeWJ. Late deep vein thrombosis and delayed weightbearing after total hip arthroplasty. Clin Orthop. 1999;361:123–130.
22.
PrandoniPBruchiOSabbionP. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty. Arch Intern Med. 2002;162(17):1966–1971.
23.
PellegriniVDDonaldsonCTFarberDC. Prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop. 2005;441:56–62.
24.
EikelboomJWQuinlanDJDouketisJD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet. 2001;358(9275):9–15.
25.
MarchettiMLiberatoNLRupertoN. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica. 1999;84(8):730–737.
26.
SarasinFBBounameauxH. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin, or nothing?Thromb Haemost. 2002;87(4):586–592.
27.
FriedmanRFDunsworthGA. Cost analysis of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop. 2000;370:171–182.
28.
HaentjensPDe GrooteKAnnemansL. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: a cost-utility analysis. Arch Orthop Trauma Surg. 2004;124(8):507–517.
29.
DouketisJDShuCSchulmanS. The risk of fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007;147(11):766–774.
30.
PrandoniPNoventaFGhirarduzziA. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199–205.
31.
HeitJAMohnDNSilversteinMD. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med. 2000;160(6):761–768.
32.
RodgerMAKahnSRWellsPS. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417–426.
33.
KyrlePAMinarEBialonczykC. The risk of recurrent venous thromboembolism in men and woman. New Eng J Med. 2004;350(25):2558–2563.
34.
McRaeSTranHSchlmanS. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368(9533):371–378.
35.
PalaretiGLegnaniCCosmiB. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost. 2005;3(5):955–961.
36.
AgnelliGPrandoniPBecattiniC. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139(1):19–25.
37.
AgnelliGPrandoniPSantamariaMG. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Eng J Med. 2001;345(3):165–169.
38.
SavoryLHarperPOckelford. Posttreatment ultrasound-detected residual venous thrombosis: a risk factor for recurrent venous thromboembolism and mortality. Curr Opin Pulm Med. 2007;13(5):403–408.
39.
PrandoniPLensingAPrinsMH. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137(12):955–960.
40.
PiovellaFCrippaLBaroneM. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis. Haematologica. 2002;87(5):515–522.
41.
SiragusaSMalatoAAnastasioR. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008;112(3):511–515.
42.
PrandoniPPrinsMHLensingA. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep vein thrombosis. Ann Intern Med. 2009;150(9):577–585.
43.
PalaretiGLegnaniCCosmiB. Risk of venous thromboembolic recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002;87:7–12.
44.
VerhovsekMDouketisJDYiQ. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(7):481–490.
45.
CosmiB. Value of D-dimer testing to decide duration of anticoagulation after deep vein thrombosis: yes. 2006;4(12):2527–2529.
46.
PalaretiGCosmiBLegnaniC. D-dimer testing to determine the duration of anticoagulation therapy. N Eng J Med. 2006;355(17):1780–1789.
47.
PalaretiGCosmiBLegnaniC. D-dimer testing to determine the duration of anticoagulant therapy. Curr Opin Pulm Med. 2007;13(5):392–397.
48.
KearonCGentMHirshJ. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340(12):901–907.
49.
SchulmanSOgrenM. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost. 2006;96(3):258–266.
50.
KearonCGinsbergJSKovacsMJ. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631–639.
51.
RidkerPMGoldhaberSZDanielsonE. Long-term, low-intensity warfarin therapy for the prevention for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425–1434.
52.
AnsellJHirshJHylekE. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(6 suppl):160S–198S.
53.
StreiffMBSegalJBTamarizLJ. Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature. Am J Hematol. 2006;81(9):684–691.
54.
LinkinsLAChoiPTDouketisJD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. A meta-analysis. Ann Intern Med. 2003;139(11):893–900.
55.
LocadiaMBossuytPStalmeierP. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost. 2004;92(6):1336–1341.
